The researchers also developed a mouse model of the mutation using CRISPR/Cas9 genome engineering to examine its effects.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification.
Two teams independently characterized Cpf1's on-target efficiency and off-target specificity, publishing their results last month.
The partnership will place the Graham Cancer Center's Gene Editing Institute under the purview of the Wistar Institute's Molecular Screening Facility.
In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.
Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.
Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.
A new report indicates that women are underrepresented among US patent holders.